TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1329300

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg thrice daily for 1 week
Number of subjects: 95

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 95

Group type: COMPARATOR
Intervention: Idiopathic stone formers
Number of subjects: 95
Study: 6462980

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Median incision
Number of subjects: 209

Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 209
Study: 31373420

Group type: EXPERIMENTAL
Intervention: Bathing adaptation (removal of bath or inaccessible shower, replacement with level access shower)
Number of subjects: 26
Study: 29251687

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) intervention including interactive student seminar, structured physical activity program focused on RT, lunchtime fitness sessions, and Web-based smartphone apps
Number of subjects: 607

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 607
Study: 27335319

Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion (MSC) program
Number of subjects: 63

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 63
Study: 24708832

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training for 16 weeks, 3 supervised sessions per week
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no exercise intervention during the 16-week period)
Number of subjects: 100
Study: 22522357

Group type: EXPERIMENTAL
Intervention: Topical MMR vaccine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Excision alone (control)
Number of subjects: 26
Study: 20429049

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (GLU) 0.2 U/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Insulin aspart (ASP) 0.2 U/kg
Number of subjects: 12
Study: 18005803

Group type: EXPERIMENTAL
Intervention: In-home early recovery management intervention delivered via Health Buddy device for 6 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 49
Study: 16055524

Group type: EXPERIMENTAL
Intervention: Subjects with AMS at high altitude
Number of subjects: 41

Group type: COMPARATOR
Intervention: Subjects without AMS at high altitude
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subjects with AMS during short-term hypoxia
Number of subjects: 41
Study: 12114885

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (n = 103)
Number of subjects: 209

Group type: COMPARATOR
Intervention: No substitution (Control group, n = 106)
Number of subjects: 209
Study: 10399787

Group type: EXPERIMENTAL
Intervention: 12 Gy of 6MV X‐rays (radiotherapy)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 103
Study: 7580551

Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg daily for 12 weeks)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Itraconazole (200 mg daily for 12 weeks)
Number of subjects: 195
Study: 2073105

Group type: EXPERIMENTAL
Intervention: Cefprozil 15 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefprozil 30 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cis isomer 15 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cis isomer 30 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trans isomer 15 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trans isomer 30 mg/kg
Number of subjects: 20
Study: 6974454

Group type: EXPERIMENTAL
Intervention: Mammary radiography screening
Number of subjects: 15748
Study: 30659782

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Secure attachment
Number of subjects: 105
Study: 28651599

Group type: EXPERIMENTAL
Intervention: synthetic CT (synCT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: CT (planCT)
Number of subjects: 11
Study: 26295638

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadobenate dimeglumine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.2 mmol/kg gadopentetate dimeglumine
Number of subjects: 20
Study: 23404949

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 121
Study: 21247601

Group type: EXPERIMENTAL
Intervention: Bilateral sacral nerve stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Percutaneous nerve evaluation test
Number of subjects: 12
Study: 19136088

Group type: EXPERIMENTAL
Intervention: Low dietary fiber intake
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Higher depressive symptoms
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Increased urinary tract symptoms
Number of subjects: 336
Study: 17785486

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8479

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 8479

Group type: EXPERIMENTAL
Intervention: Decrease in Cornell product (continuous variable)
Number of subjects: 8479

Group type: EXPERIMENTAL
Intervention: Greater-than-median decrease in Cornell product (dichotomous variable)
Number of subjects: 8479

Group type: EXPERIMENTAL
Intervention: In-treatment decrease of Cornell product (continuous variable)
Number of subjects: 8479

Group type: EXPERIMENTAL
Intervention: In-treatment reduction in Cornell product of 236 mm x msec or more
Number of subjects: 8479
Study: 16135349

Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (IV PCA) with morphine (1.5 mg; lockout interval, 8 min)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve sheath block (FNB)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (EPI)
Number of subjects: 45
Study: 12297207

Group type: EXPERIMENTAL
Intervention: Dietary supplement (bean extract)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 10995137

Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide in oxygen
Number of subjects: 34

Group type: COMPARATOR
Intervention: 40% oxygen in air
Number of subjects: 34
Study: 7480615

Group type: EXPERIMENTAL
Intervention: AIDS education program
Number of subjects: 1709
Study: 2312918

Group type: EXPERIMENTAL
Intervention: Group information about the disease
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Individual information about the disease
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Provision of the whole information at once
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Division of the information into three parts separated by 15 minutes
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Overall information provided
Number of subjects: 48
Study: 533575

Group type: EXPERIMENTAL
Intervention: 250 mg antipyrine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 500 mg antipyrine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1000 mg antipyrine
Number of subjects: 5
Study: 31274487

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Tranexamic acid (TA)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: EACA
Number of subjects: 114

Group type: COMPARATOR
Intervention: TA
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: EACA and TA
Number of subjects: 114
Study: 28488078

Group type: EXPERIMENTAL
Intervention: Linguistic context presentation of vocabulary
Number of subjects: 64

Group type: COMPARATOR
Intervention: Explicit definition presentation of vocabulary
Number of subjects: 64
Study: 24191873

Group type: EXPERIMENTAL
Intervention: Plasma of argon cleaning treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (abutment subjected only to usually adopted cleaning protocol by steam)
Number of subjects: 30
Study: 23289009

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (daily oral Zn supplements for eight weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No supplements (control group)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 65
Study: 21258242

Group type: EXPERIMENTAL
Intervention: Amniotic membrane (AM)
Number of subjects: 102
Study: 18976257

Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA) 800 mg day(-1) for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16923843

Group type: EXPERIMENTAL
Intervention: Parents' interest in poisoning (81%)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Parents' interest in car crashes (49%)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Childhood injury risk for poisoning
Number of subjects: 105

Group type: COMPARATOR
Intervention: Childhood injury risk for fires
Number of subjects: 105

Group type: COMPARATOR
Intervention: Childhood injury risk for falls
Number of subjects: 105

Group type: COMPARATOR
Intervention: Childhood injury risk for car crashes
Number of subjects: 105
Study: 15124551

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (5-FU-CDDP)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Concomitant radiotherapy (5FU‐MMC)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Dose escalation of the boost from 15 Gy to 25-25 Gy
Number of subjects: 222
Study: 10795929

Group type: EXPERIMENTAL
Intervention: Vasopressin V2 antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (fluid restriction and treatment of underlying disorder)
Number of subjects: 0
Study: 8698956

Group type: EXPERIMENTAL
Intervention: Stimulus narrowing using prepackaged foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular food
Number of subjects: 0
Study: 1577025

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (20 mg.day‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3831143

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg three times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 30
Study: 31329991

Group type: EXPERIMENTAL
Intervention: 12% RPS diet
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 18% RPS diet
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 12% and 18% RPS diets
Number of subjects: 600

Group type: COMPARATOR
Intervention: 0% RPS diet (control)
Number of subjects: 600
Study: 28861843

Group type: EXPERIMENTAL
Intervention: Somatosensory discrimination training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Simple object manipulation (Control)
Number of subjects: 39
Study: 27418251

Group type: EXPERIMENTAL
Intervention: Trabectedin treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 5
Study: 24034685

Group type: EXPERIMENTAL
Intervention: Advertisements for alternative nicotine products
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Advertisements for soft drinks
Number of subjects: 1062

Group type: EXPERIMENTAL
Intervention: Relevant advertisements
Number of subjects: 1062
Study: 22486134

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg daily for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21138627

Group type: EXPERIMENTAL
Intervention: Study group (without anti-viral therapy)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (received lamivudine therapy)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Antiviral group (HBeAg negative)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Antiviral group (HBeAg positive)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Antiviral group
Number of subjects: 177
Study: 18702961

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus N-acetylcysteine (NAC)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Isotonic saline plus N-acetylcysteine (NAC)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus NAC
Number of subjects: 502

Group type: COMPARATOR
Intervention: Isotonic saline plus NAC
Number of subjects: 502
Study: 15995439

Group type: EXPERIMENTAL
Intervention: Epinephrine-augmented hypotensive epidural anesthesia without use of a tourniquet (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normotensive epidural anesthesia with use of a tourniquet (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epinephrine-augmented hypotensive epidural anesthesia (Group A)
Number of subjects: 100
Study: 12859561

Group type: EXPERIMENTAL
Intervention: IL-8
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diluent (placebo)
Number of subjects: 12
Study: 10473963

Group type: EXPERIMENTAL
Intervention: Retinol (ROL)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Retinaldehyde (RAL)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Retinoic Acid (RA)
Number of subjects: 361
Study: 8933962

Group type: EXPERIMENTAL
Intervention: 2 hr of bedrest after angiography using five or six French catheters
Number of subjects: 205

Group type: COMPARATOR
Intervention: 4 hr of bedrest after angiography using five or six French catheters
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 2 hr of bedrest after angiography using seven French catheters
Number of subjects: 205

Group type: COMPARATOR
Intervention: 4 hr of bedrest after angiography using seven French catheters
Number of subjects: 205
Study: 1932377

Group type: EXPERIMENTAL
Intervention: Interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6416184

Group type: EXPERIMENTAL
Intervention: Futraful alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MMC and Futraful
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMC alone
Number of subjects: 0
Study: 29895522

Group type: EXPERIMENTAL
Intervention: Repeat antenatal betamethasone
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study: 29734536

Group type: EXPERIMENTAL
Intervention: TAP and RS blocks (Group B)
Number of subjects: 36
Study: 25102853

Group type: EXPERIMENTAL
Intervention: VMP (bortezomib plus melphalan and prednisone)
Number of subjects: 260

Group type: COMPARATOR
Intervention: VTP (bortezomib plus thalidomide and prednisone)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: VMP
Number of subjects: 260

Group type: COMPARATOR
Intervention: VTP
Number of subjects: 260
Study: 22329593

Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 80

Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 80
Study: 20597558

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate injection plus thumb spica cast
Number of subjects: 73

Group type: COMPARATOR
Intervention: Casting alone
Number of subjects: 73
Study: 18728131

Group type: EXPERIMENTAL
Intervention: Perpendicular technique (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tangential technique (group B)
Number of subjects: 45
Study: 16191750

Group type: EXPERIMENTAL
Intervention: Nicotine (20 microg/kg) via nasal spray
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (0 microg/kg) via nasal spray
Number of subjects: 17
Study: 12165576

Group type: EXPERIMENTAL
Intervention: SLI381 10 mg
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: SLI381 20 mg
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: SLI381 30 mg
Number of subjects: 584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study: 10100391

Group type: EXPERIMENTAL
Intervention: Lexical-semantic information retention
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Other types of information (pictures, shapes, propositional information)
Number of subjects: 1
Study: 7776160

Group type: EXPERIMENTAL
Intervention: Intrasulcular laser Doppler readings (LDR) with stabilizing stent
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intrasulcular laser Doppler readings (LDR) without stabilizing stent
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Local anesthetic with vasoconstrictor
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stent stabilized LDR
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hand held LDR
Number of subjects: 9
Study: 2321781

Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric (IG/IH) nerve block with 0.25 ml/kg of 0.25% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Instillation nerve block with up to 0.5 ml/kg of 0.25% bupivacaine
Number of subjects: 60
Study: 91434

Group type: EXPERIMENTAL
Intervention: cis-platinum, vinblastine, and bleomycin combination chemotherapy
Number of subjects: 126
Study: 30738344

Group type: EXPERIMENTAL
Intervention: External focus of attention instructions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Internal focus of attention instructions
Number of subjects: 20
Study: 28052291

Group type: EXPERIMENTAL
Intervention: Yogurt containing Lactobacillus gasseri OLL2716 (LG), 112 ml twice daily for 6 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo yogurt, 112 ml twice daily for 6 weeks
Number of subjects: 64
Study: 25886517

Group type: EXPERIMENTAL
Intervention: Web-based information tool and nurse-delivered telephone support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 23651614

Group type: EXPERIMENTAL
Intervention: Nurse-led indicated stepped-care program for depressive symptoms
Number of subjects: 236

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 236
Study: 21593577

Group type: EXPERIMENTAL
Intervention: Intensive intervention (systemic corticosteroid for 2 weeks, inhaled corticosteroid for 16 weeks, bronchodilator(s))
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (current asthma treatment guidelines for 18 weeks)
Number of subjects: 142
Study: 21348985

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17565246

Group type: EXPERIMENTAL
Intervention: Radiotherapy (doses more than 60 Gy) in post menopausal cases
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: 3 weeks short course irradiation (Canadian protocol) or accelerated partial breast irradiation
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Breast irradiation with concurrent chemotherapy
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Post mastectomy regional irradiation
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Chemotherapy first before irradiation
Number of subjects: 941
Study: 14748938

Group type: EXPERIMENTAL
Intervention: Lutein, beta-carotene, or lycopene (natural isolate capsules, 15 mg/d, 4 weeks)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lycopene or lutein (>2.00 micromol/l)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Carotenoids (0.50 to 1.00 micromol/l)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control cells (no carotenoid supplementation)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control PBL
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: PBL DNA resistance to oxidative damage ex vivo
Number of subjects: 3
Study: 11240091

Group type: EXPERIMENTAL
Intervention: Single global assessment of treatment efficacy (5-point scale)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aspirin 600/650 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 11180023

Group type: COMPARATOR
Intervention: Rofecoxib 12.5 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rofecoxib 50 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rofecoxib 25 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rofecoxib 12.5 mg, 25 mg, 50 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8742572

Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg/daily)
Number of subjects: 18
Study: 1449887

Group type: EXPERIMENTAL
Intervention: Meglumine diatrizoate
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 180
Study: 6398026

Group type: EXPERIMENTAL
Intervention: Fluorometholone acetate 0.1%
Number of subjects: 0
Study: 31427334

Group type: EXPERIMENTAL
Intervention: Oral glucose lowering drugs (OGLDs) starting with metformin and supplemented as needed with glibenclamide.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin therapy.
Number of subjects: 0
Study: 30019747

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 100
Study: 27393274

Group type: EXPERIMENTAL
Intervention: Chemoembolization with TANDEM™ loaded with 150 mg of doxorubicin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Chemoembolization with TANDEM™ loaded with 100 mg of doxorubicin
Number of subjects: 71

Group type: COMPARATOR
Intervention: High loading group (150 mg doxorubicin)
Number of subjects: 71
Study: 24332254

Group type: EXPERIMENTAL
Intervention: Intervention cohort (n=65)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Both groups (intervention and SOC)
Number of subjects: 98
Study: 22976568

Group type: EXPERIMENTAL
Intervention: Intra-ligamental anaesthesia with 4% articaine with epinephrine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Negative aspiration of blood after ILA
Number of subjects: 36
Study: 21319602

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency (PRF) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18379478

Group type: EXPERIMENTAL
Intervention: Afobazole (30 to 60 mg daily, mean 50 mg) for 6 weeks
Number of subjects: 32
Study: 16081755

Group type: EXPERIMENTAL
Intervention: Custom made mouthguard (MG)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control (usual mouthguard behaviours) (C)
Number of subjects: 301
Study: 11851576

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/d
Number of subjects: 7705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705

Group type: EXPERIMENTAL
Intervention: Raloxifene (both doses) in subset with increased cardiovascular risk
Number of subjects: 7705
Study: 10209802

Group type: EXPERIMENTAL
Intervention: estradiol-noretisteron acetate treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48